MedTrace Logo

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-11-03

No results posted yet for this study

Summary

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.

Conditions

  • Crohn Disease
  • Diabetic Gastroparesis

Interventions

DRUG

Rifaximin

550 mg by mouth three times daily for 14 days

DRUG

Placebo

By mouth three times daily for 14 days

Sponsors & Collaborators

Principal Investigators

  • Brian E Lacy · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-14
Primary Completion
2025-04-08
Completion
2025-04-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04254549 on ClinicalTrials.gov